Diffuse Systemic Sclerosis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Seronegative Arthritis, Systemic Lupus Erythematosus
Conditions
Brief summary
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS). Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA. These 5 cohorts will be subject to standardized clinical monitoring.
Detailed description
This study is proposed by the Rheumatology and Pediatrics departments of the 3 French-speaking Universities. The first objective will be to include a progressive number of new young patients (≤ 50 years) in order to optimize and standardize care and clinical response objectives. The number of 25% of new incident cases will be sought with an increase of 20% each year during the 5 to 10 years of this project. Population: JIA, RA/UA, SLE, dSS (American Congres of Rheumatology criteria). Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA. These 5 cohorts will be subject to standardized clinical monitoring and specific objectives that will make it possible to analyze the number of patients with a good control of the disease and/or a clinical remission, defined according to the international criteria.
Interventions
None listed
Sponsors
Université Catholique de Louvain
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
2 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative / psoriatic / undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria). * Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.
Exclusion criteria
* Treated for \> 3 months * \> 50 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission rate or absence of synovitis in Rheumatoid arthritis patients | Through the entire study, during approximately 15 years |
Other
| Measure | Time frame |
|---|---|
| Remission rates improvement in Juvenile arthritis (JIA) patients | Through the entire study, during approximately 15 years |
| Reduction in damage rate in Systemic Lupus Erythematosus patients | Through the entire study, during approximately 15 years |
| Inclusion of at least 80% of the incident cases of diffuse Systemic sclerosis | Through the entire study, during approximately 15 years |
Countries
Belgium
Contacts
Primary ContactPatrick Durez
Outcome results
None listed